

New appointments at Avecia Biologics

Tees Valley, 5 August 2008 : Avecia Biologics has announced the following recent appointments:

Non Executive Director

Dr. Colman Casey has been appointed as Non-Executive Director of Avecia Biologics. Dr. Casey has many years' experience in biopharmaceutical manufacturing, most recently as General Manager of Schering Plough's Brinny facility in Ireland. He is currently a Director of the University College Cork Education/Training Partnership and he will retain these duties in alongside his new role at Avecia.

Steve Bagshaw, President Avecia Biologics said "We are delighted that Dr. Casey has agreed to join Avecia as non-executive director. His experience will be hugely beneficial as we continue our growth and take a number of projects through Process Validation into commercial manufacture."

Head of Business Development, Europe

Koen Hellendoorn has been appointed Head of Business Development for Europe. Dr Hellendoorn joined Avecia in April 2005 as Business Development Manager covering Benelux, Germany and Israel. In his new role Dr Hellendoorn will be responsible for leading the European business development team and key account management. Prior to joining Avecia he was director of global technology alliances with Cambridge, UK-based Biovation.

About Avecia

Avecia is a privately owned biotechnology group of companies with recognised leading positions in the process development and manufacture of biopharmaceutical and oligonucleotide medicines. The Group's Biologics Business, based in Tees Valley, UK site has been developing processes and making protein-based biologics to cGMP since 1998. Products currently being worked on include medicines targeted at forms of cancer, heart conditions, stroke, growth and blood disorders. In Milford, MA, the group's OligoMedicines business carries out process development and the manufacture of oligonucleotide therapeutics by

sequential solid state synthesis to produce pharmaceuticals comprised of short strands of DNA or RNA. Customers range from some of the world's largest pharmaceutical companies to small innovative biotech start-up businesses.

For further information contact:

Bridget Hall

Communications Manager

Tel : +44 (0)1642 367320

Mobile : +44 (0)7796 938929

Fax : +44 (0)1642 364463

E-mail : bridget.hall@avecia.com

Paul White

Recognition PR

Tel : +44 (0)1325 363436

Fax : +44 (0)1325 353471

E-mail : andrew.lambert@recognitionpr.co.uk